Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Genocea Biosciences (GNCAQ)
OTHER OTC:GNCAQ
Holding GNCAQ?
Track your performance easily
GNCAQ Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range― - ―
Previous Close$0.02
Volume2.28K
Average Volume (3M)N/A
Market Cap
$59.00
Enterprise Value-$12.45M
Total Cash (Recent Filing)$20.10M
Total Debt (Recent Filing)$7.65M
Price to Earnings (P/E)―
Beta160.05
Next Earnings
Feb 16, 2023EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding58,783,503
10 Day Avg. Volume1,057,991
30 Day Avg. VolumeN/A
Standard Deviation0.27
R-Squared0.12
Alpha-0.07
Financial Highlights & Ratios
Price to Book (P/B)0.04
Price to Sales (P/S)8.71
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue-6.52
Enterprise Value/Gross Profit-7.59
Enterprise Value/Ebitda0.36
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Ownership Overview
69.84%
Insiders
0.00% Mutual Funds
0.02% Other Institutional Investors
30.14% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
GNCAQ FAQ
What was Genocea Biosciences’s price range in the past 12 months?
Currently, no data Available
What is Genocea Biosciences’s market cap?
Currently, no data Available
When is Genocea Biosciences’s upcoming earnings report date?
Genocea Biosciences’s upcoming earnings report date is Feb 16, 2023 which is 582 days ago.
How were Genocea Biosciences’s earnings last quarter?
Currently, no data Available
Is Genocea Biosciences overvalued?
According to Wall Street analysts Genocea Biosciences’s price is currently Overvalued.
Does Genocea Biosciences pay dividends?
Genocea Biosciences does not currently pay dividends.
What is Genocea Biosciences’s EPS estimate?
Genocea Biosciences’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Genocea Biosciences have?
Genocea Biosciences has 58,783,504 shares outstanding.
What happened to Genocea Biosciences’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Genocea Biosciences?
Currently, no hedge funds are holding shares in GNCAQ
---
Company Description
Genocea Biosciences
Genocea Biosciences, Inc. engages in the development and commercialization of cancer vaccines. It uses its proprietary technology platform ATLAS, to identify clinically relevant antigens of T cells based on actual human immune responses. Its product candidates include GEN-003, an investigational immunotherapy for the treatment of genital herpes; and GEN-009, a neoantigen cancer vaccine. The company was founded by Robert Paull and Kevin J. Bitterman on August 16, 2006 and is headquartered in Cambridge, MA.
---
---